Trevi Therapeutics

TRVI

Market cap $1.53B

The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 102.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and David Hastings, Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, at 9:20 a.m.

Statistically-s ignificant reduction in the relative change from baseline in 24-hour objective cough frequency observed across all dose groups of nalbuphine ER at Week 6 with statistically-significant cough reduction as early as Week 2, the first time point measured Over 60% of nalbuphine ER-treated patients achieved at least a 50% reduction in 24-hour cough frequency at Week 6 vs baseline Patient-reported outcome measure of cough frequency was consistent with reduction observed with objective cough monitoring NEW HAVEN, Conn., Jan. 22, 2026 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that the key results from the Phase 2b CORAL trial of oral nalbuphine ER for the treatment of chronic cough in patients with IPF have been published in the Journal of the American Medical Association (JAMA).

FDA End-of-Phase 2 meeting scheduled to take place in the first quarter of 2026 for the chronic cough program in patients with idiopathic pulmonary fibrosis Phase 2b refractory chronic cough trial planned to initiate in the first half of 2026 NEW HAVEN, Conn., Jan. 8, 2026 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced strategic updates ahead of its participation in the 15th Annual LifeSci Partners Corporate Access Event taking place in San Francisco, CA, from January 12-14, 2026.

Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth NEW HAVEN, Conn. , Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that David Hastings will assume the role of Chief Financial Officer effective January 6, 2026.

Trevi Therapeutics (TRVI) is initiated with a "Buy" rating, driven by its lead asset Haduvio's advancement toward phase 3 testing for chronic cough in IPF. Company's Haduvio demonstrated statistically significant efficacy in phase 2b CORAL study [IPF] and phase 2a RIVER [RCC], with a differentiated dual central/peripheral mechanism of action. The company is well-capitalized, with $194.9M in cash and a projected runway into 2028, supporting upcoming pivotal trials.

Trevi Therapeutics, Inc. ( TRVI ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Jennifer Good - Co-Founder, CEO, President, Interim Principal Financial Officer & Director James Cassella - Chief Development Officer Farrell Simon - Chief Commercial Officer Conference Call Participants Ryan Deschner - Raymond James & Associates, Inc., Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Judah Frommer - Morgan Stanley, Research Division Serge Belanger - Needham & Company, LLC, Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division William Wood - B. Riley Securities, Inc., Research Division Kaveri Pohlman - Clear Street LLC Presentation Operator Good afternoon, and welcome to the Trevi Therapeutics Third Quarter 2025 Earnings Conference Call.

Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026 Company ended the third quarter of 2025 with $194.9 million in cash, cash equivalents and marketable securities with expected cash runway into 2028 Management to host a conference call and webcast today at 4:30 p.m. EST NEW HAVEN, Conn.

Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.

Fireside Chat with Management on Tuesday, November 11, 2025, at 3:20 p.m. ET NEW HAVEN, Conn.